Neuroprotective potential of ionotropic glutamate receptor antagonists

@article{Danysz2009NeuroprotectivePO,
  title={Neuroprotective potential of ionotropic glutamate receptor antagonists},
  author={W. Danysz and C. Parsons},
  journal={Neurotoxicity Research},
  year={2009},
  volume={4},
  pages={119-126}
}
From the therapeutic point of view, the real challenge is not only to improve the symptoms, but to interfere with the pathomechanism of the disease. That is why a considerable interest has recently been devoted to developing glutamate receptors antagonists (mainly of the NMDA type) for acute and chronic neurodegeneration. Developing such a treatment that slows down the progression of the disease is extremely time and costs consuming. At present there is consensus that competitive NMDA receptor… Expand
NMDA-gated ion channel research and its therapeutic potentials in neurodegenerative diseases: a review
TLDR
Open-channel blockers with uncompetitive antagonism and drugs modulating NMDAR activities are appealing therapeutic strategies because, in theory, these properties could decrease neurotoxicity due to excessive levels of glutamate while sparing physiological neurotransmission. Expand
The fraction of activated N-methyl-d-Aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole
TLDR
The fraction of NMDA receptors contributing to postsynaptic events in the presence of therapeutically relevant concentrations of the GRI riluzole was determined using an in vitro hippocampal slice preparation and it is likely that NMDA receptor antagonists would be able to exert additional therapeutic effects in combination therapy with GRIs. Expand
Novel NMDA receptor modulators: an update
TLDR
First-in-class potentiators and subunit-selective agents form the basis for most new strategies, complemented by efforts to limit off-target liability and fine-tune on-target properties. Expand
In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons
TLDR
Therapeutic doses of memantine are able to antagonize NMDA receptor-mediated activity in the principal cells of the hippocampus in vivo, i.e. in the presence of physiological concentrations of Mg2+. Expand
GAP-43 is essential for the neurotrophic effects of BDNF and positive AMPA receptor modulator S18986
TLDR
GAP-43 is an important mediator of the neurotrophic effects of S18986 and BDNF on neuronal survival and plasticity, and is essential for the success of positive AMPA receptor modulator-BDNF-based neurotrophin therapy. Expand
Neurotoxicological and neuroprotective elements in Parkinson’s disease
TLDR
The potential of neural transplants is explored in the proposal that Sertoli cells,or specific neural cells, or placental blood stem cells will find “routine” use instead of fetal neural cells in the treatment of last-resort for PD. Expand
Fear memory impairing effects of systemic treatment with the NMDA NR2B subunit antagonist, Ro 25-6981, in mice: Attenuation with ageing
TLDR
Evidence is provided of the memory impairing effects of selective blockade of NR2B-containing NMDARs, and loss of these effects with ageing is shown, which could ultimately have implications for elucidating the pathophysiology of learning dysfunction in neuropsychiatric disorders and ageing. Expand
A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists – in vitro characterization
TLDR
Three novel uncompetitive NMDA receptor antagonists based on an amino-alkylcyclohexane structure with moderate affinity have good therapeutic indices in a variety of in vivo behavioural models where glutamate is known to play a pivotal role and should prove to be useful therapeutics in a wide range of CNS disorders. Expand
The tricyclic antidepressant desipramine inhibited the neurotoxic, kainate-induced [Ca2+]i increases in CA1 pyramidal cells in acute hippocampal slices
TLDR
The multitarget action on decisive players of excitotoxicity holds out more promise in clinical therapy of neurodegenerative diseases. Expand
Evaluation of anticonvulsants for possible use in neuropathic pain.
TLDR
This review is focusing on antiepileptic drugs, which are evaluated for their analgesic activity in major tests related with neuropathic pain, and examples are carbamazepine, gabapentin, and lacosamide as drugs well established in epilepsy market. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 100 REFERENCES
Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data
TLDR
Preclinical data on memantine is summarized to provide evidence that it is indeed possible to develop clinically well tolerated NMDA receptor antagonists, a fact reflected in the recent interest of several pharmaceutical companies in developing compounds with similar properties to memantine. Expand
Glutamate in CNS disorders as a target for drug development: an update.
The authors provide an extensive review of new data related to the role of glutamate in CNS disorders, describing new aspects in glutamate and glutamatergic receptors-NMDA receptors, NR2B-selectiveExpand
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease.
TLDR
The clinical use of NMDA antagonists may prove useful in Parkinson's disease to treat symptoms and retard disease progression and there is evidence that the beneficial effects of anticholinergic drugs and amantadine may be mediated by NMDA receptor blockade. Expand
Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat
TLDR
The results of these studies suggest that the cytotoxicity of ibotenate to NBM cholinergic cells is not dependent upon stimulation of metabotropic glutamate receptors, but results from activation of N-methyl-D-aspartate (NMDA) receptors. Expand
MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis.
TLDR
A potential neuroprotective action of NMDA receptor antagonists, memantine and amantadine in particular, can be seen at low doses lacking side effects, according to the ratio of the ED50 for the side effects observed, including ataxia, myorelaxation and stereotypy, and theED50 for neuroprot protective ability. Expand
Excitatory amino acids and Parkinson's disease
SIR: Recently, Klockgether and Turski proposed that antagonists of excitatory amino acids may be beneficial in the treatment of Parkinson's disease 1. This suggestion , previously put torward byExpand
Prospects of glutamate antagonists in the therapy of Parkinson's disease
TLDR
Glutamate is directly involved in the functional alterations of basal ganglia circuitry that lead to the development of parkinsonian motor symptoms, and drugs counteracting the effects of glutamate might provide new protective and symptomatic strategies for therapy of PD. Expand
NMDA and AMPA Receptor Antagonists in Global and Focal Ischemia
This chapter highlights the importance of N -methyl- D -aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate (AMPA) receptor antagonists in global and focal ischemia models. GlobalExpand
Glutamate, excitotoxicity and amyotrophic lateral sclerosis
TLDR
Eight lines of evidence that indicate a disturbance of glutamatergic neurotransmission in ALS patients are reviewed and the links between abnormal activation of glutamate receptors and other potential mechanisms of neuronal injury, including activation of calcium-mediated second messenger systems and free radical mechanisms, are emphasised. Expand
Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist.
TLDR
Selfotel was not an effective treatment for acute ischemic stroke and a trend toward increased mortality, particularly within the first 30 days and in patients with severe stroke, suggests that the drug might have a neurotoxic effect in brain ischemia. Expand
...
1
2
3
4
5
...